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Comparison of first-line and 
second-line terlipressin versus sole 
norepinephrine in fulminant ovine 
septic shock
Tim G. Kampmeier1, Philip H. Arnemann1, Michael Hessler1, Laura M. Seidel1, Karsten Becker  2, 
Andrea Morelli3, Sebastian W. Rehberg4 & Christian Ertmer1
The Surviving Sepsis Guidelines suggest the use of vasopressin in case of catecholamine-refractory 
septic shock. Terlipressin (TP) as a V1-selective AVP analogue is a potential alternative, though data 
regarding the first-line administration in septic shock are scarce. The present study explored and 
compared the effects of first-line vs. second-line infusion of TP or sole norepinephrine regarding 
organ function, fluid and norepinephrine requirements and survival in fulminant ovine septic shock. 
Peritoneal sepsis was induced in 23 ewes after laparotomy and faecal withdrawal from the caecum. 
After onset of shock, causal and supportive sepsis therapy (antibiotics, peritoneal lavage, fluids and 
open-label norepinephrine) was performed in all animals. Concurrently, animals were randomized 
to receive 0.9% sodium chloride (control group) or TP (2 µg∙kg−1∙h−1, first-line group) after shock 
onset. In the second-line TP group, TP (2 µg∙kg−1∙h−1) was started once norepinephrine requirements 
exceeded 0.5 µg∙kg−1∙min−1. No significant differences were found between groups regarding survival, 
haemodynamics as well as fluid- and catecholamine-requirements. Kidney function and electron 
microscopic kidney injury were comparable between groups. In the present model of fulminant ovine 
septic shock, first-line TP infusion had no significant effect on fluid and norepinephrine requirements or 
organ dysfunction as compared to second-line TP infusion or placebo.
Patients with septic shock commonly require large doses of catecholamines to maintain a sufficient mean arterial 
pressure (MAP). According to the current sepsis guidelines, norepinephrine is the vasopressor of choice in the 
treatment of sepsis related vasodilation1. However, there is increasing evidence that high catecholamine doses 
may have detrimental effects and is associated with increased mortality2,3. Thus, alternative, non-adrenergic vas-
opressors are desirable as first- or second-line treatment of sepsis-associated vasodilation.
The current sepsis guidelines suggest the vasopressin receptor agonist arginine-vasopressin (AVP) as 
second-line treatment if MAP cannot be maintained by norepinephrine alone. The second indication for 
non-adrenergic vasopressors is to reduce to dose of norepinephrine needed. First-line AVP therapy however, is 
discouraged by the guidelines in fear of ischemic end-organ events. Additionally, the reluctant use of AVP in clin-
ical settings might be based on low experience and the fear of clinicians regarding intestinal or digital ischemia as 
well as reduced global oxygen delivery and cardiac output4,5. In contrast, evidence suggests that rather sepsis itself 
is the reason for such complications, and the use of vasopressin analogues does not trigger ischemic events6,7. 
Notably, administration of AVP in septic patients has been proven safe as supplemental (The Vasopressin in Septic 
Shock (VASST)-Trial) as well as first-line therapy (Vasopressin vs Norepinephrine on Kidney Failure in Patients 
With Septic Shock (VANISH)- Trial)8,9.
Notably, AVP is not available in several countries. Instead, the vasopressin-receptor agonist terlipressin 
(TP) is commonly used. TP has a higher selectivity for the V1a-receptor than AVP, and has been demonstrated 
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equally or more effective than AVP in experimental and small clinical trials10–12. A single centre randomized con-
trolled trial by Svoboda and colleagues with 30 patients investigated the effects of terlipressin administration in 
catecholamine-resistant septic shock. The authors concluded that continuous terlipressin infusion was ineffective 
in reduction of catecholamine requirements and mortality if applied in the late phase of catecholamine-resistant 
septic shock13. On the other hand, the previous published TERLIVAP-trial, which compared the effects of first-line 
AVP versus first-line TP in septic shock patients described a reduction in catecholamine requirements and lower 
rates of new onset tachyarrhythmias within the TP group14. Moreover, experimental data suggest, that V1 agonists 
may reduce sepsis-associated endothelial injury and capillary leakage, thus favouring early treatment initiation15,16.
Notably, no studies have yet investigated first-line versus second-line treatment with TP as a continuous infusion in 
septic shock. Therefore, the present study was designed to explore the effects of first-line continuous low-dose adminis-
tration of TP versus second-line administration (which is the common situation in the clinical setting) regarding fluid 
and norepinephrine requirements as well as organ function and survival in fulminant ovine septic shock.
Material and Methods
Animal care. After arrival in the research facility, the animals were housed in flocks of 3 to 10 animals under 
veterinary supervision. Veterinary care attendants visited the sheep twice a day and more often when neces-
sary. A veterinary examination of health status took place on arrival, prior to inclusion in the study and when-
ever deemed necessary by the veterinary care attendants. All methods were performed in accordance with the 
National Institutes of Health Guide and as well as the American Physiologic Society’s “Guide for the Care and Use 
of Laboratory Animals” using established protocols.
Instrumentation. After approval by the Animal Care Committee of the State Government of North-Rhine 
Westphalia (LANUV NRW, Recklinghausen, Germany) with the approval (ref no. 8.87–50.10.37.09.194), 23 
healthy female sheep (median body weight 42.0 kg, 34.0–43.5; 25th− 75th percentile) were anaesthetized by intra-
muscular injection of S-ketamine (Ketanest® S, 10 mg·kg−1, Parke-Davis, Berlin, Freiburg, Germany) and mida-
zolam (Dormicum®, 0.3 mg·kg−1, Hoffmann-La Roche AG, Grenzach-Wyhlen, Germany). The ewes were held 
in abstinence from food for 12 hours prior to the instrumentation with free access to water. After endotracheal 
intubation with a 9.0 tracheal tube (Rüsch, Rüschelit©, Teleflex Medical GmbH, Kernen, Germany), anaesthe-
sia was maintained by inhalational isoflurane with an expiratory fraction of 1.0–1.5% (Forene®; Abbott GmbH 
& Co. KG, Wiesbaden, Germany). A quadlumen central venous catheter (6 Fr. Quadlumen Catheter Set, PVB 
Medizintechnik GmbH, Kirchseeon, Germany) was placed using Seldinger’s technique into the right jugular vein 
through which anaesthesia was supplemented with S-ketamine (1 mg·kg−1·h−1), midazolam (0.3 mg·kg−1·h−1) 
and lidocain (1.5 mg·kg−1·h−1)17 during the further instrumentation. For continuous hemodynamic surveillance, 
a pulse contour cardiac output (PiCCO) catheter was placed in the right femoral artery (5 Fr.; Pulsion Medical 
Systems, Munich, Germany) with connection to a transpulmonary thermodilution and pulse contour cardiac out-
put computer (PiCCO2, Pulsion Medical Systems, München, Germany). A Foley catheter (12 Fr. urinary catheter, 
Porgès S.A., Le Plessis Robinson-Cedex, France) was inserted to determine urinary output.
Surgical preparation. Following a median laparotomy, the cecum of the animals was detected and incised 
in order to withdraw 1.5 g·kg−1 faeces. A contamination of the peritoneal cavity was strictly avoided. Two 16 Fr. 
drains were placed in the mesentery of the small intestine and the abdomen was closed with continuous suture 
afterwards. After a 2 hours’ phase of recovery, baseline (BL) data were assessed to examine whether the animals 
fulfil the inclusion criteria.
Inclusion criteria. The following criteria had to be fulfilled at BL before inclusion in the study:
•	 Heart rate (HR) < 100 bpm
•	 Mean arterial pressure (MAP) 70–120 mmHg
•	 Cardiac index (CI) 2.5–6.0 L·min−1·m2
•	 Serum lactate ≤1,2 mmol·l−1
•	 Temperature 38.0–39.8 °C
•	 Arterial pH: 7.30–7.50
•	 Arterial carbon dioxide pressure 35–55 mmHg.
The inclusion criteria were based on reference values for healthy sheep18.
Induction of septic shock. After inclusion in the study, autologous faeces were injected into the abdominal 
cavity via one of the 16 Fr. drain. Onset of septic shock was defined as
•	 MAP <60 mm Hg and
•	 Serum lactate concentration ≥1.8 mmol·l−1 (i.e. 1.5 times the upper normal limit of sheep18) and
•	 Minimum of four hours after instillation of the faeces.
After the onset of septic shock, “shock time” measurements were performed as detailed below.
Randomization. After the “shock time” measurements, the animals were randomly assigned to one of the 
following study groups:
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•	 Control (n = 7)
[study solu tion 1: 0.9% saline; study solution 2: 0.9% saline]
•	 Terlipressin first-line (n = 8)
[study solution 1: TP (2 µg∙kg−1∙h−1); study solution 2: 0.9% saline]
•	 Terlipressin second-line (n = 8)
[study solution 1: 0.9% saline; study solution 2: TP (2 µg∙kg−1∙h−1)].
The attendant investigators were blinded for study group allocation and content of study drug syringes. Study 
solution 1 was started immediately after randomisation. The second study solution was initiated when norepi-
nephrine requirements exceeded 0.5 µg∙kg−1∙min−1. Once initiated, both study solutions were administered with 
a fixed infusion rate until the end of the protocol.
Study protocol. After randomization, study solution 1 was started as specified in the group description and 
continued throughout the whole experiment. Causal therapy was initiated by intravenous antimicrobial therapy 
with a bolus infusion of 20 mg·kg−1 meropenem (Meronem©, AstraZeneca GmbH, Wedel, Germany) and fol-
lowed by continuous intravenous infusion with 2.5 mg·kg−1·h−1. Furthermore, peritoneal lavage was initiated by 
fractional instillation of four litres of warm (38° Celsius) saline through the abdominal drains until no more faecal 
contamination was detected.
Supportive fluid therapy was based on dynamic and volumetric hemodynamic parameters. Indications for 
fluid resuscitation were:
•	 Global enddiastolic volume index (GEDI) < 620 mL·m−2 or < BL1 value
•	 Stroke volume variation (SVV) > 13%
•	 Haematocrit (Hct) > BL1 value.
Contraindications for fluid resuscitation were:
•	 Extravascular lung water index (ELWI) ≥ 17 mL·kg−1
•	 Horowitz-Index (PaO2/FiO2) <2.
Fluid resuscitation was performed with hydroxyethyl starch (HES) 6% 130/0.4 (Volulyte©, Fresenius Kabi, 
Bad Homburg, Germany) and balanced crystalloids (Sterofundin© ISO, B. Braun Melsungen, Germany). HES 
and crystalloids were applied alternately (250 ml HES followed by 500 ml crystalloid) until the maximum dose of 
HES was reached (50 mL·kg−1). If necessary, further fluid resuscitation was performed with crystalloids only until 
hemodynamic indicators were met.
Norepinephrine was initiated at the onset of shock and titrated to maintain a MAP ≥65 mmHg up to a max-
imum dose of 5 µg·kg−1·h−1. If norepinephrine requirements exceeded 0.5 µg∙kg−1∙min−1, the second study 
solution was initiated as detailed in the group description and continued until the end of the experiment. The 
maximum dose of norepinephrine was drawn from clinical experience, when no more vasoconstrictive effect of 
the substance could be expected due to tachyphylactic effects.
Measurements. Hemodynamic parameters, urinary output as well as arterial and central-venous blood gas 
analyses were documented at BL, shock time and hourly thereafter. Blood and urine samples for laboratory and 
microbiological analyses were taken at BL, shock time and every four hours afterwards. The samples were imme-
diately centrifuged and stored at −70 °C for later analyses.
Analysed laboratory variables. The following variables were determined from blood and urine samples, 
respectively:
•	 Blood gas analyses (electrolytes, oxygen- and carbon dioxide partial pressure, pH, base excess (BE), haemo-
globin, haematocrit, oxygen saturation, lactate, glucose).
•	 Parameters of organ (dys-) function (bilirubin, aspartate aminotransferase (ASAT), alanine aminotransferase 
(ALAT), serum creatinine concentration, serum urea concentration, creatinine-clearance).
Aerobic and anaerobic blood cultures were withdrawn under sterile conditions at BL, shock time as well as 
8 h, 16 h and 24 h afterwards.
End of protocol and autopsy. At the end of the 24 hours interventional period after shock time the animals 
were killed in deep propofol anaesthesia (4 mg·kg−1) with a bolus injection of 100 ml of 1-molar potassium chlo-
ride solution. All animals were autopsied with removal and weighing of the heart, lungs, kidneys and terminal 
ileum. Additionally, samples from the kidney were collected for electron microscopic analyses.
Electron microscopy. Transmission electron microscopy (TEM) was performed with a Philips 
CmlO-Electronic microscope (Philips, Eindhoven, Netherlands) at 80 kV. Cellular damage, cellular oedema and 
mitochondrial damage was quantified by a pathologist who was blinded for the protocol. Ultrastructural kidney 
damage was quantified according to the “electron microscopic tubular injury” (EMTI) score19. This score contains 
the four criteria (1) vacuolar degeneration and swelling of organella, (2) dissociation of epithelium and basal 
membrane, (3) epithelial cell injury and (4) intratubular precipitation. Each criterion was scored from 0 to 3, thus 
the total EMTI score (sum of the four criteria) could range from 0 to 12 points19.
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Statistical analysis. Statistical analysis was performed with IBM SPSS statistics software version 22 (IBM, 
Armonk, New York, United States). All data are presented as median and interquartile range (IQR). Comparisons 
between groups for variables measured only once were made using Kruskal-Wallis H-test. If necessary, post-hoc 
comparisons were conducted using Dunn’s test. Comparisons between time points were made using Wilcoxon 
signed-rank test. Comparisons between groups for repeatedly measured variables were conducted by calculation 
of generalized estimating equations (GEE) with group as factor and time as covariate20. Asymptotic two-sided 
p-values smaller than 0.05 were assumed as statistically significant.
Data availability. The datasets generated and analysed during the current study are available from the cor-
responding author on reasonable request.
Results
Features of septic shock (prior to study drug infusion). All animals developed septic shock between 
BL and shock time with reductions in MAP, CI and with lactic acidosis (see Supplemental Digital Content 1 
Table 1, BL versus shock time data). Renal function decreased during this time and acute kidney injury occurred, 
which was classified according to the KDIGO guidelines21 using diuresis and creatinine concentration (see 
Supplemental Digital Content 1 Table 1, BL versus shock time data).
Hemodynamic and oxygen transport variables (during study drug infusion). There were no dif-
ferences between the study groups regarding hemodynamic variables (see Table 1, Supplemental Digital Content 2 
Fig. 1 and Supplemental Digital Content 3 Fig. 2, cardiac index and heart rate). Haematocrit was higher within the 
TP second-line group (p < 0.05) as compared to TP first-line group (see Supplemental Digital Content 4 Fig. 3, 
Haematocrit concentration). All other measured parameters of oxygen transport were comparable between the 
study groups (see Table 2).
Fluid and norepinephrine requirements. There were no differences between the study groups regarding 
cumulative fluid and norepinephrine requirements (see Figs 1, 2 and 3) over the 24-hour interventional period, 
though the catecholamine-requirements in the TP first-line group tended to be lower without statistical signifi-
cance (median norepinephrine requirements per body weight per hours alive [µg·kg−1·h−1]: control group 57.2 
[30.9; 287.9]; TP first-line 30.3 [6.1; 79.3]; TP second-line 66.6 [37.7; 107.3]). The initiation of the second study 
solution was after 6.0 h [4.0; 11.5] in the control group, 5.0 h [2.0; 6.0] in the TP first-line group and 6.0 h [5.0; 6.0] 
in the TP second-line group. Mean start of the second study solution over all groups was 6.2 h [±4.1] after shock 
time. The cumulative fluid requirements of the TP groups were lower as compared to the control group without 
statistical significance (see Figs 1 and 3).
Variable Group Shock time 4 h 8 h 16 h 24 h
CVP [mmHg]
Control 1 [0; 4] 7 [4; 8] 5 [2; 13] 11 [9; 17] 17 [12; 18]
TP first-line 1 [0; 2] 4 [1; 9] 7 [2; 11] 5 [3; 9] 12 [7; 13]
TP second-line 0 [0; 0] 2 [1; 4] 4 [2; 7] 8 [4; 10] 12 [6; 14]
EVLWI [mL·kg-1]
Control 13 [12; 17] 14 [11; 15] 14 [10; 15] 12 [11; 12] 12 [11; 17]
TP first-line 14 [12; 21] 14 [12; 15] 15 [13; 18] 13 [12; 15] 12 [11; 13]
TP second-line 13 [12; 16] 13 [12; 16] 14 [13; 19] 14 [11; 19] 11 [11; 13]
GEDI [mL·m−2]
Control 606 [494; 644] 760 [728; 848] 741 [642; 781] 631 [572; 695] 641 [616; 766]
TP first-line 599 [528; 739] 791 [665; 847] 740 [668; 833] 691 [665; 788] 700 [603; 730]
TP second-line 509 [409; 595] 725 [663; 801] 708 [683; 810] 686 [596; 720] 656 [598; 788]
MAP [mmHg]
Control 40 [36; 54] 60 [56; 61] 60 [58; 61] 63 [60; 64] 62 [61; 63]
TP first-line 46 [35; 49] 60 [50; 62] 61 [59; 63] 64 [63; 64] 61 [60; 61]
TP second-line 39 [34; 41] 58 [58; 61] 60 [56; 61] 63 [61; 65] 60 [54; 60]
SVI [mL·m−2]
Control 28 [24; 35] 57 [48; 70] 57 [44; 74] 48 [45; 66] 59 [47; 74]
TP first-line 24 [19; 30] 39 [36; 52] 57 [41; 66] 45 [44; 50] 50 [38; 57]
TP second-line 23 [21; 29] 50 [45; 58] 56 [48; 62] 33 [23; 56] 33 [23; 56]
SVRI [dyn·s/cm−5·m−2]
Control 1497 [1208; 1883] 630 [449; 1037] 612 [515; 1001] 727 [548; 926] 846 [458; 886]
TP first-line 1352 [1276; 1912] 729 [513; 946] 680 [518; 1000] 993 [799; 1223] 741 [609; 1028]
TP second-line 1509 [1434; 1647] 666 [617; 857] 603 [531; 718] 818 [638; 1037] 741 [559; 1405]
SVV [%]
Control 11 [8; 13] 12 [11; 15] 11 [9; 16] 12 [9; 16] 14 [10; 18]
TP first-line 8 [5; 11] 10 [9; 16] 13 [12; 14] 12 [10; 12] 14 [12; 15]
TP second-line 16 [11; 19] 12 [11; 14] 15 [11; 17] 11 [10; 14] 14 [10; 19]
Table 1. Haemodynamics of the study groups during the 24-hour interventional period. Values are presented 
as median [interquartile range]. CVP, central venous pressure; EVLWI, extravascular lung water index; GEDI, 
global end-diastolic index; SVI, stroke volume index; SVRI, systemic vascular resistance index; SVV, stroke volume 
variation; TP, Terlipressin.
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Figure 1. Cumulative fluid amount of the study animals. The figure demonstrates the cumulative fluid amounts 
of the study animals over the 24-hour interventional period. Data are presented as median [interquartile range].
Variable Group Shock time 4 h 8 h 16 h 24 h
pH(a) [-lg c(H+)]
Control 7.44 [7.38; 7.48] 7.45 [7.43; 7.48] 7.42 [7.40; 7.45] 7.38 [7.16; 7.40] 7.22 [6.99; 7.27]
TP first-line 7.39 [7.37; 7.44] 7.41 [7.35; 7.46] 7.42 [7.34; 7.45] 7.31 [7.23; 7.31] 7.20 [7.20; 7.24]
TP second-line 7.45 [7.40; 7.49] 7.43 [7.40; 7.45] 7.39 [7.33; 7.44] 7.28 [7.10; 7.41] 7.10 [6.80; 7.31]
BE [mmol·L−1]
Control 7.0 [3.5; 8.5] 3.0 [2.2; 4.5] 2.2 [−0.3; 3.7] −2,4 [−5.4; 1.7] −5.6 [−7.2; −3.4]
TP first-line 4.9 [2.1; 5.4] 1.0 [0.4; 1.9] 0.8 [−2.3; 1.9] −3.3 [−3.6; −2.6] −5.5 [−6.7; −5]
TP second-line 6.6 [3.5; 7.4] 2.3 [1.4; 2.8] 1.4 [0.7; 3.2] −3.2 [−7.1; 0.8] −6.1 [−6.5; −4.9]
DO2I [mL·min−1·m−2]
Control 314 [251; 353] 608 [484; 727] 600 [456; 675] 467 [339; 642] 486 [348; 624]
TP first-line 415 [387; 657] 585 [507; 605] 543 [376; 661] 473 [331; 588] 559 [369; 674]
TP second-line 243 [210; 357] 563 [418; 642] 669 [497; 793] 565 [488; 695] 466 [399; 481]
VO2I [mL·min−1·m−2]
Control 118 [98; 130] 79 [74; 91] 80 [65; 107] 74 [52; 101] 66 [47; 79]
TP first-line 167 [107; 221] 120 [93; 130] 86 [55; 116] 63 [43; 66] 58 [43; 73]
TP second-line 123 [90; 138] 97 [70; 105] 76 [64; 107] 72 [59; 92] 48 [44; 62]
O2-ER [mL·min−1·m−2]
Control 40 [39; 45] 14 [12; 19] 15 [11; 22] 19 [13; 21] 17 [11; 19]
TP first-line 37 [31; 42] 19 [14; 27] 14 [11; 20] 13 [10; 17] 11 [7; 17]
TP second-line 48 [36; 52] 20 [14; 24] 14 [11; 16] 13 [12; 15] 16 [10; 18]
ScvO2 [%]
Control 61 [60; 65] 85 [82; 87] 84 [80; 87] 81 [80; 84] 80 [79; 86]
TP first-line 69 [64; 73] 84 [77; 88] 85 [78; 90] 87 [81; 90] 85 [78; 90]
TP second-line 53 [47; 64] 83 [78; 86] 88 [83; 90] 82 [78; 87] 69 [60; 84]
Temperature [°C]
Control 39.4 [39.2; 40.1] 39.3 [38.7; 39.9] 39.4 [39.1; 40.0] 39.2 [38.7; 39.4] 39.5 [38.5; 39.6]
TP first-line 40.0 [39.8; 40.5] 39.6 [38.9; 40.6] 39.7 [38.4; 40.9] 39.7 [38.7; 41.2] 39.6 [39.0; 41.1]
TP second-line 40.3 [39.9; 40.4] 39.2 [39.1; 39.6] 39.6 [39.3; 40.0] 39.9 [39.4; 40.1] 39.7 [39.2; 40.9]
Table 2. Metabolism, oxygenation and temperature of the study groups during the 24-hour interventional 
period. Values are presented as median [interquartile range]. BE, base excess; DO2I, oxygen delivery index; 
O2-ER, oxygen extraction rate; pH(a), arterial potentia hydrogenii; ScvO2, central venous oxygen saturation; TP, 
Terlipressin; VO2I, oxygen consumption index.
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Organ function and EMTI-Score. All animals developed acute kidney injury at shock time, which per-
sisted despite study therapy (see Table 3). Kidney function and injury were comparable between groups as meas-
ured by serum creatinine, creatinine clearance, diuresis and EMTI score (see Fig. 4 and Table 3).
All animals developed an increase of liver enzymes over the interventional period. The animals of the TP 
first-line group showed significantly elevated ASAT and ALAT as compared to the control group (each p < 0.05, 
see Supplemental Digital Content 5 Fig. 4 and Supplemental Digital Content 6 Fig. 5, ASAT and ALAT). Serum 
vasopressin levels were lower in the control group as compared to the TP groups (each p < 0.05, see Table 3).
Figure 3. Cumulative fluid requirements per hour. The figure demonstrated the cumulative fluid requirements 
of the study animals over time within the 24-hour interventional period. The average initiation-points of the 
study solutions are highlighted in the figure. (A) Shock time and initiation of the 1st study solution. (B) Average 
start of the 2nd study solution. Data are presented as mean [standard deviation].
Figure 2. Cumulative norepinephrine amount of the study animals. The figure demonstrates the cumulative 
norepinephrine dose of the study animals averaged over the 24-hour interventional period. Data are presented 
as median [interquartile range].
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Variable Group Shock time 4 h 8 h 16 h 24 h
Lactate [mmol·L−1]
Control 1.8 [1.8; 1.9] 2.7 [2.4; 3.0] 2.9 [2.5; 3.2] 2.9 [2.7; 3.2] 2.2 [1.8; 3.8]
TP first-line 1.9 [1.9; 2.0] 3.3 [3.1; 3.5] 3.6 [2.9; 3.9] 3.3 [2.3; 3.5] 2.6 [2.5; 3.2]
TP second-line 1.8 [1.8; 2.2] 2.6 [2.2; 2.9] 2.6 [2.3; 3.5] 2.8 [2.1; 4.7] 3.3 [3.1; 3.6]
Creatinine [mmol·L−1]
Control 1.5 [1.2; 1.7] 1.1 [0.9; 1.2] 1.2 [1; 1.4] 1.1 [0.9; 1.7] 1.3 [1.1; 2.3]
TP first-line 1.8 [1.3; 1.9] 1.4 [1.1; 1.8] 1.5 [1.1; 1.6] 2.2 [0.9; 2.3] 2.1 [1.2; 2.5]
TP second-line 1.3 [1.2; 2.0] 1.1 [0.8; 1.2] 1.4 [0.8; 1.6] 1.6 [1.3; 2.0] 1.9 [1.6; 2.6]
Crea- Clearance 
[mL·min-1·m−2]
Control 11 [4; 39] 55 [34; 73] 65 [43; 69] 32 [10; 53] 14 [9; 22]
TP first-line 0 [0; 8] 60 [41; 83] 41 [21, 68] 55 [25; 55] 4 [0; 36]
TP second-line 3 [0; 9] 61 [40; 96] 50 [21; 70] 16 [6; 36] 0 [0; 18]
Diuresis [mL·kg−1·h−1]
Control 0.1 [0.1; 0.4] 0.9 [0.5; 1.6] 0.5 [0.2; 1.0] 0.6 [0.2; 1.2] 0.6 [0.3; 0.9]
TP first-line 0 [0; 0.1] 1.2 [0.7; 2.4] 0.3 [0; 0.7] 0.4 [0.4; 0.6] 0.1 [0; 0.3]
TP second-line 0.1 [0; 0.1] 0.8 [0.7; 2.0] 0.3 [0.2; 0.5] 0.4 [0.3; 0.6] 0.2 [0; 0.4]
Bilirubin [mg·dL−1]
Control 0.1 [0.1; 0.8] 0.1[0.1; 0.1] 0.1 [0.1; 0.1] 0.1 [0.1; 0.1] 0.1 [0.1; 0.1]
TP first-line 0.1 [0.1; 0.1] n.a. 0.1 [0.1; 0.1] 0.1 [0.1; 0.1] 0.1 [0.1; 0.1]
TP second-line 0.1 [0.1; 0.1] 0.1 [0.1; 0.8] 0.1 [0.1; 0.1] 0.1 [0.1; 0.2] 0.1 [0.1; 0.1]
Protein [g·dL−1]
Control 4.1 [3.9; 4.5] 1.9 [1.4; 2.3] 1.5 [1.0; 1.9] 1.1 [0.8; 1.7] 1.4 [1.4; 1.5]
TP first-line 4.3 [4.1; 5.0] 1.8 [1.5; 2.5] 1.3 [1.1; 1.9] 1.8 [1.0; 1.9] 1.9 [1.3; 2.0]
TP second-line 4.6 [4.1; 5.1] 1.9 [1.5; 2.3] 1.3 [1.1; 1.8] 1.3 [1.2; 1.8] 1.4 [1.3; 1.8]
Arginine vasopressin 
[pg·mL−1]
Control 239 [195; 291] 8 [5; 12] 11 [3; 96] 9 [4; 19] 9 [8; 14]
TP first-line 104 [30; 163] 5 [4; 10] 8 [4; 28] 15 [3; 20] 10 [8; 15]
TP second-line 257 [190; 273] 6 [4; 24] 12 [5; 20] 16 [12; 25] 25 [8; 40]
Table 3. Parameters of organ function of the study groups during the 24-hour interventional period. Values are 
presented as median [interquartile range]. Bilirubin, serum bilirubin concentration; Crea-Clearance, creatinine 
clearance; Creatinine, serum creatinine concentration; Protein, serum protein concentration; TP, Terlipressin.
Figure 4. EMTI score of the study animals. The figure demonstrates the electronic microscopy injury (EMTI) 
score of the animals analysed in kidney biopsies. EMTI, electronic microscopy tubular injury. Data are 
presented as median [interquartile range].
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All other measured variables of organ function as well as organ weights and relative organ weights showed no 
differences between the study groups (see Table 3 and Supplemental Digital Content 7 Table 2, Organ weights).
Blood cultures. The blood cultures taken at BL were mostly sterile or contained single bacteria of the skin 
flora, whereas a broad spectrum of intestinal bacteria was detected in the blood cultures taken at shock time. The 
bacterial load decreased over the interventional period. Enterococcus faecium was the most frequently detected 
bacterial species at the end of the study (see Supplemental Digital Content 8 Figure 6, results from blood cultures).
Survival. In the control-group and the TP first-line group, each five of eight animals survived the interven-
tional period (62.5%). Six of eight animals survived in the TP second-line group (75%). The mean survival times 
were 23.6 h (23.1; 24) in the TP second-line group followed by the control-group [20.8 h (17.6; 23.9)] and the TP 
first-line group [19.6 h, 16.6; 23.6)]. There were no statistically significant differences between the groups regard-
ing 24- h survival (see Fig. 5).
Discussion
The present study compared the effects of a first-line versus second-line therapy with continuous low-dose TP 
in ovine septic shock on fluid- and catecholamine requirements as well as organ function and survival. All study 
animals developed septic shock with hyperlactatemia and acidosis as well as organ dysfunction with the onset of 
septic shock. Haemodynamics were characterized by a hyperdynamic circulation with high-dose norepinephrine 
requirements. There were no differences regarding amounts of intravenous fluids or catecholamines and survival 
between the study groups, though the animals of the TP first-line group tended to receive lower amounts of nor-
epinephrine. No other relevant side effects of terlipressin were detected. Furthermore, no differences between the 
groups regarding kidney function as measured by diuresis, creatinine or ultrastructural kidney damage quantified 
by electronic microscopic could be observed.
Septic shock induced in the present study matched the definition of the current international consensus defini-
tions of sepsis and septic shock (Sepsis-3), which define sepsis as a life-threatening organ dysfunction caused by a 
dysregulated host response following infection22. Furthermore, these criteria require not only sepsis with persisting 
hypotension and the need for vasopressors to maintain a MAP ≥ 65 mmHg but also hyperlactatemia despite ade-
quate volume resuscitation22. Infection was induced successfully with peritonitis and consecutive bacteraemia, 
which was proven by blood cultures (see Supplemental Digital Content 8 Figure 6, results from blood cultures).
A small pilot-trial investigated the effects of first-line AVP versus TP in human septic shock (TERLIVAP). 
Within this RCT, first-line continuous low-dose administration of TP reduced catecholamine requirements more 
effectively as compared to AVP and also reduced the risk of new onset tachyarrhythmia14. There were no significant 
differences in norepinephrine requirements between the study groups in the present study, which is an unex-
pected result that contradicts previous data. One possible explanation might be the dosage of the administered 
Figure 5. Survival of the study animals. The figure illustrates survival of the study animals over the 24-hour 
interventional period in a Kaplan-Meyer diagram.
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study solutions. Although the applied dose in the study animals (2 µg∙kg−1∙h−1) was higher than the dosage in the 
TERLIVAP trial (1.3 µg∙kg−1∙h−1), which was able to show a significant reduction in catecholamine requirements14, 
underdosing of TP in the present study must be considered as a possible explanation. This is especially true since 
the required norepinephrine doses were higher than 1 µg∙kg−1∙min−1 in many animals, suggesting a very severe 
vasodilatory shock state. The persistent bacteraemia in the present trial might also be interpreted as a sign of severe 
disease. Since haemodynamics and infection could not be sufficiently stabilized, the present model may be regarded 
as refractory septic shock. The results from the “Vasopressin and Septic Shock Trial” (VASST) demonstrated ben-
eficial effects of vasopressin administration only in patients with less-severe septic shock8, which is another expla-
nation why the therapeutic strategies used in the present trial were ineffective. Other studies using terlipressin 
in ovine systemic inflammation demonstrated reduction of catecholamine requirements, however, these trials 
were performed in endotoxemia and not in animals with fulminant abdominal sepsis11. In the TERLIVAP trial, 
significant differences regarding catecholamine requirements between the study groups were measured at least 
24 hours after study drug initiation. Thus, another explanation for the lack of differences regarding catecholamine 
requirements might be the length of the present observational period. Maybe significant differences in catecho-
lamine requirements need some time to occur with continuous infusion of TP, whereas bolus infusion shows 
immediate hemodynamic effects23. It is finally possible, that in severe shock states not only norepinephrine but 
also non-adrenergic vasopressors need dose adjustment. However, further increase of the terlipressin dose might 
be associated with increased adverse effects and should therefore be investigated carefully in future trials. There 
is currently no data available regarding the long-term effects of terlipressin on organ function or adverse effects. 
Svoboda and colleagues investigated continuous terlipressin administration in catecholamine-refractory septic 
shock and described no adverse effects13. Yildizdas et al. used terlipressin as a bolus rescue-therapy in children 
suffering from septic shock and described no adverse effects or detrimental organ affection as well24. Together with 
the mentioned findings from the TERLIVAP-trial (observational period 48 hours), administration of TP in sepsis 
seems to be safe in short-term use. However, though the half-life of terlipressin is quite low, one cannot exclude 
that potential harmful effects on organ function might occur with delay (>48 hours) and were not monitored in the 
available studies. Accordingly, future trials on terlipressin in sepsis should consider longer observational periods 
and follow-up of the patients with focus on long-term organ failure.
Furthermore, species related differences in (receptor-)physiology may also play a role in this context25. AVP 
and its synthetic analogues (especially TP) are potent vasopressors, causing vasoconstriction by activation of vas-
opressin (V)-receptors. While arginine-vasopressin (AVP) has an identical affinity to the (vascular) V1 receptor 
as compared to the (renal) V2 receptor (V1/V2-ratio of 1), terlipressin is more V1-selective (V1/V2-ratio of 2.2) 
in humans. It should be considered, that this receptor affinity may differ in sheep. Other studies demonstrated 
beneficial effects of terlipressin in ovine endotoxemia11, however, the observed effects did not prove that the 
V1/V2-ratio is comparable to human beings.
Increases in haemoglobin and haematocrit levels in septic patients are commonly interpreted as a conse-
quence of both hypovolemia and capillary leakage26. The observed increase in haematocrit at shock time indicates 
that relevant capillary leakage was induced in the present model. Though the cumulative fluid requirements and 
organ weights were comparable between groups, the haematocrit of the TP second-line group raised significantly 
over the 24-hour period as compared to the TP first-line group. This might indicate more severe capillary leakage 
in the TP second-line group, although serum lactate concentrations and catecholamine requirements were com-
parable between the study groups and offer no hints for a higher severity of septic shock. Additionally, one would 
expect more fluid requirements in case of higher capillary leakage, however, the cumulative fluid requirements 
tended to be lower in the TP groups as compared to the control group.
Regarding organ function, there were no differences in acute kidney injury or tubular damage of the animals 
between the study groups as measured by retention parameters, urinary output and EMTI score. However, there 
were some differences between the groups in the measured liver enzymes which should be addressed in the fol-
lowing. TP is commonly used in the clinical setting to treat variceal bleeding of the oesophagus. The mechanism 
behind this is a vasoconstrictive effect of TP on dilated splanchnic blood vessels with consecutive reduction of 
blood flow and pressure in the portal vein27. The increase of liver enzymes in the TP first-line group of the pres-
ent investigation could be explained by a reduced liver perfusion due to the described mechanism. On the other 
hand, it has been shown that the reduction in portal venous blood flow by vasopressin agonists is compensated 
by an increase in hepatic arterial blood flow (so called hepatic artery buffer response)28,29. Furthermore, no differ-
ences regarding bilirubin levels were observed.
In the TERLIVAP-trial, the investigated septic patients who received continuous low-dose TP showed reduced 
levels of serum bilirubin as compared to the patients who were treated with norepinephrine or vasopressin. There 
were no differences between the study patients regarding ASAT, ALAT and activated partial thromboplastin time 
ratio (aPTTr)14. Nevertheless, the observed increase in ASAT and ALAT in the present study appears to be a clear 
pharmacological effect of TP, since it was most pronounced in the TP first-line group and less pronounced in the 
second-line group, whereas ASAT and ALAT activities were lowest in the control group. The relevance of this 
finding should be focussed in future studies.
There are some limitations in the present study which should be addressed:
Since the study was performed in an animal model, results and conclusions should be transferred to clin-
ical settings with caution. Though the hemodynamic pattern of healthy and septic sheep is similar to human 
beings30,31, the effects of vasoactive substances may be different between species, especially regarding the sub-
structure of the vasopressin receptors and the V1/V2 ratio. Furthermore, though the model is of clinical relevance, 
one should consider that septic shock was fulminant, and thus any pharmacological intervention may have been 
futile. It must be noted, that the 24-hour observational period in the present study is quite short for a complex dis-
ease like sepsis and for detection of long-term terlipressin effects. Another limitation of the present investigation 
was the use of HES in septic shock, which was an accepted strategy at the time of initiation of the study with the 
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mentioned maximum dose of 50 ml·kg−1 BW32. Since fluid therapy was identical among group, this should not 
induce a relevant bias. Furthermore, the antimicrobial therapy with meropenem failed to eliminate Enterococcus 
faecium (natural resistance against carbapenems) in blood cultures. In future studies using the present model, 
antimicrobial chemotherapy might include additional gram-positive coverage, e.g. vancomycin.
Conclusion
In the present study, first-line versus second-line administration of continuous low-dose terlipressin in fulminant 
ovine septic shock had no influence on norepinephrine and fluid requirements, organ injury or 24-h survival. No 
beneficial effects of terlipressin were observed, most likely due to the fulminant sepsis with refractory vasoplegia 
or consecutive underdosing of terlipressin in relation to the severity of the shock state.
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